Targeting ART1: A Potential Drug or Biomarker for Various Diseases

Target Name: ART1

NCBI ID: G417

ART1

Targeting ART1: A Potential Drug or Biomarker for Various Diseases

ART1 (NAR1_HUMAN), a protein that is expressed in various tissues of the human body, has been identified as a potential drug target or biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and various functions make it an attractive target for researchers to study and develop new treatments.

The NAR1 gene, which encodes the ART1 protein, is located on chromosome 12q34 and has been implicated in various cellular processes in the human body. The protein encoded by this gene is a 21-kDa transmembrane protein that plays a critical role in the development, maintenance, and regulation of the blood-brain barrier (BBB), which is a barrier that separates the brain from the surrounding blood vessels and is responsible for maintaining the integrity of the brain's microenvironment.

The ART1 protein has been shown to be involved in various physiological processes, including cell adhesion, migration, and invasion. It has also been shown to play a role in the regulation of angiogenesis, the process by which new blood vessels are formed, and in the regulation of neurotransmitter release and synaptic plasticity.

In addition to its role in the BBB, ART1 has also been shown to be involved in the regulation of inflammation and immune responses. It has been shown to play a role in the regulation of T cell responses and has been implicated in the development of multiple sclerosis, an autoimmune disorder.

Given its various functions and its involvement in various diseases, ART1 has become a focus of interest for researchers as a potential drug target or biomarker. Studies have shown that ART1 can be targeted by small molecules, including those that inhibit its function as a signaling molecule.

One of the most promising strategies for targeting ART1 is the use of small molecules that can inhibit its function as a G protein-coupled receptor (GPCR). GPCR is a family of transmembrane proteins that play a critical role in cellular signaling. By inhibiting the activity of ART1, small molecules can reduce the formation of blood-brain barrier and inhibit the migration and invasion of cancer cells.

Another strategy for targeting ART1 is the use of small molecules that can modulate its expression level. Many diseases are caused by the over-expression of genes, including ART1. By developing small molecules that can modulate the expression level of ART1, researchers can potentially reduce the number of diseases caused by the over-expression of this gene.

In addition to its potential as a drug target or biomarker, ART1 has also been shown to be a potential biomarker for various diseases. Its expression has been shown to be associated with the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. By using techniques such as qRT-PCR, researchers have been able to demonstrate that the expression of ART1 is associated with the development of these diseases.

In conclusion, ART1 (NAR1_HUMAN) is a protein that has been shown to be involved in various cellular processes in the human body. Its unique structure and various functions make it an attractive target for researchers to study and develop new treatments. The potential of ART1 as a drug target or biomarker makes it a promising area of research for the development of new treatments for a variety of diseases. Further studies are needed to fully understand the role of ART1 in various diseases and to develop effective treatments.

Protein Name: ADP-ribosyltransferase 1

Functions: Has ADP-ribosyltransferase activity toward GLP1R

The "ART1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ART1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets